GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » Debt-to-Equity
中文

Rigel Pharmaceuticals (Rigel Pharmaceuticals) Debt-to-Equity : -2.12 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals Debt-to-Equity?

Rigel Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.9 Mil. Rigel Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $52.7 Mil. Rigel Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-28.6 Mil. Rigel Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was -2.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rigel Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

RIGL' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.05   Med: 0.68   Max: 1.15
Current: -2.12

During the past 13 years, the highest Debt-to-Equity Ratio of Rigel Pharmaceuticals was 1.15. The lowest was -3.05. And the median was 0.68.

RIGL's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs RIGL: -2.12

Rigel Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Rigel Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Debt-to-Equity Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 1.15 1.01 -3.05 -2.12

Rigel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.05 -2.50 -2.16 -1.91 -2.12

Competitive Comparison of Rigel Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Rigel Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Debt-to-Equity falls into.



Rigel Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rigel Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Rigel Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rigel Pharmaceuticals  (NAS:RIGL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Rigel Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Executives
Raul R Rodriguez officer: Sr VP of Bus Dev and Com Ops 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos officer: EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer officer: EVP & CMO 5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno officer: EVP & Chief Financial Officer 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey officer: EVP, GC & Corp Sec 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan officer: Principal Accounting Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii officer: EVP & Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel officer: EVP Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080